Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading SciSparc鈥檚 latest clinical update can mean sorting through dozens of SEC exhibits, technical trial data, and shifting cash-runway notes. If you have ever wondered, 鈥淗ow do I track SciSparc insider trading Form 4 transactions before the market reacts?鈥� you are not alone. Biotech filings are dense, and SciSparc鈥檚 dual focus on cannabinoid drug trials and hemp-product revenues makes them even more layered.
Stock Titan solves the problem. Our AI dissects every SciSparc quarterly earnings report 10-Q filing, highlights R&D spend, and links trial milestones so you can act quickly. Want the cash-burn figures without scrolling? Need SciSparc annual report 10-K simplified line-by-line? Prefer SciSparc Form 4 insider transactions real-time delivered the moment they hit EDGAR? It鈥檚 all here, alongside AI-powered summaries that turn medical jargon into plain language. We also cover every 8-K; search 鈥�SciSparc 8-K material events explained鈥� and arrive straight at our tagged excerpts.
Whether you鈥檙e monitoring understanding SciSparc SEC documents with AI, comparing drug-development timelines, or checking a SciSparc proxy statement executive compensation, our platform offers:
- AG真人官方-time alerts for SciSparc executive stock transactions Form 4
- AI summaries that answer 鈥淪ciSparc SEC filings explained simply鈥� in seconds
- Complete coverage of S-1s, 10-Ks, 10-Qs, 8-Ks, and more鈥攚ith direct links to exhibits
- Contextual metrics: dilution risk, patent counts, and trial phase progress
No more digging through 200-page PDFs. Stock Titan鈥檚 expert analysis and instant updates transform SciSparc earnings report filing analysis into actionable insight you can trust.
SciSparc announced that shareholders approved all proposals at their adjourned annual general meeting held on June 26, 2025. The meeting resulted in the approval of two significant documents:
- A new amended and restated articles of association
- An updated compensation policy for executive officers and directors
These approvals were obtained with the requisite majority in accordance with Israeli Companies Law and the company's existing articles of association. The proposals were previously detailed in a proxy statement furnished to the SEC on May 21, 2025.
The Form 6-K filing will be incorporated into multiple company registration statements, including several Form F-3s (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408) and Form S-8s (File Nos. 333-278437, 333-225773, 333-286791). The document was signed by Oz Adler, Chief Executive Officer.
SciSparc has filed an amended F-4 registration statement regarding its proposed merger with AutoMax Motors. The merger agreement, initially signed on April 10, 2024, and amended multiple times through May 8, 2025, will result in AutoMax becoming a wholly-owned subsidiary of SciSparc.
Key terms of the merger include:
- AutoMax shareholders and advisor will own approximately 49.99% of SciSparc's share capital post-merger
- SciSparc shareholders will retain approximately 50.01% ownership
- SciSparc will maintain its Nasdaq listing under symbol "SPRC"
- Expected closing in Q3 2025, subject to shareholder and court approvals
A special shareholder meeting is scheduled for August 13, 2025 to vote on: merger approval, new indemnification agreements for directors/officers, executive bonuses contingent on merger closing, and election of new board members. Post-merger, Oz Adler will serve as CEO/CFO, with Dr. Adi Zuloff-Shani as CTO.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
